Details of Disease

General Information of Disease (ID: DISKA5RC)

• Disease Name: Tardive dyskinesia
• Synonyms: tardive dyskinesia (disease); tardive dyskinesia
• Disease Class: 8A02: Dystonic disorder
• Disease Hierarchy:
  DISYKSRF: Genetic disease
  DISKA5RC: Tardive dyskinesia
• ICD Code:
  ICD-11: ICD-11: 8A02.10
  Expand ICD-11: '8A02.10
• Disease Identifiers:
  MONDO ID: MONDO_0010096
  MESH ID: D000071057
  UMLS CUI: C0686347
  OMIM ID: 272620
  MedGen ID: 151939
  HPO ID: HP:0040141

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Deutetrabenazine	DMUPFLI	Approved	Small molecular drug	[1]
Valbenazine Tosylate	DMQSA2V	Approved	Small molecular drug	[2]
Ingrezza	DMVPLNC	Phase 4	Small molecular drug	[3]

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
SOM3355	DMKCBSM	Phase 2	NA	[4]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 17 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ADORA2A	TTM2AOE	Limited	Biomarker	[5]
ADORA3	TTJFY5U	Limited	Biomarker	[6]
DRD1	TTZFYLI	Limited	Genetic Variation	[7]
HSPG2	TT5UM29	Limited	Biomarker	[8]
CHRM1	TTZ9SOR	Strong	Genetic Variation	[9]
CHRM2	TTYEG6Q	Strong	Genetic Variation	[9]
GABRB2	TTZA1NY	Strong	Biomarker	[10]
GABRG3	TTEX6LM	Strong	Biomarker	[10]
HTR1F	TT0MI3F	Strong	Genetic Variation	[11]
HTR2C	TTWJBZ5	Strong	Genetic Variation	[12]
HTR3A	TTPC4TU	Strong	Genetic Variation	[13]
HTR6	TTJS8PY	Strong	Genetic Variation	[11]
MTNR1B	TT32JK8	Strong	Biomarker	[14]
SLC18A2	TTNZRI3	Strong	Genetic Variation	[15]
SLC6A11	TT8RXO5	Strong	Genetic Variation	[10]
TAAR5	TTCO25G	Strong	Biomarker	[16]
TOR1A	TTF85KW	Strong	Genetic Variation	[17]

This Disease Is Related to 1 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
CYP4F3	DEFCMPI	Limited	Genetic Variation	[18]

This Disease Is Related to 11 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
FUZ	OTC427QQ	Limited	Genetic Variation	[19]
DPP6	OTWW3H0K	Strong	Biomarker	[20]
GFRA2	OT34CXNN	Strong	Genetic Variation	[21]
GRK6	OT4LZTP9	Strong	Biomarker	[22]
MCF2L	OTEURA8N	Strong	Genetic Variation	[23]
NRXN1	OTJN1JQA	Strong	Biomarker	[24]
PGP	OT6QQ7OR	Strong	Genetic Variation	[25]
PIP4K2C	OTHRWR93	Strong	Biomarker	[26]
PPIG	OTZ8BTTM	Strong	Genetic Variation	[25]
RGS9	OTRA1LOC	Strong	Genetic Variation	[27]
TAF1	OTDYS5G4	Strong	Genetic Variation	[28]

References

• [1] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
• [3] ClinicalTrials.gov (NCT03698331) The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine. U.S. National Institutes of Health.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] No involvement of the adenosine A2A receptor in tardive dyskinesia in Russian psychiatric inpatients from Siberia.Hum Psychopharmacol. 2012 May;27(3):334-7. doi: 10.1002/hup.2226.
• [6] Adenosine Hypothesis of Antipsychotic Drugs Revisited: Pharmacogenomics Variation in Nonacute Schizophrenia.OMICS. 2016 May;20(5):283-9. doi: 10.1089/omi.2016.0003.
• [7] Analysis of genetic variations in the dopamine D1 receptor (DRD1) gene and antipsychotics-induced tardive dyskinesia in schizophrenia.Eur J Clin Pharmacol. 2011 Apr;67(4):383-388. doi: 10.1007/s00228-010-0967-2. Epub 2010 Dec 22.
• [8] Tardive dyskinesia: Who gets it and why.Parkinsonism Relat Disord. 2019 Feb;59:151-154. doi: 10.1016/j.parkreldis.2018.11.017. Epub 2018 Nov 15.
• [9] Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of CHRM1 and CHRM2 muscarinic receptors.World J Biol Psychiatry. 2020 Jan;21(1):72-77. doi: 10.1080/15622975.2018.1548780. Epub 2019 Jan 9.
• [10] Gaba transporter SLC6A11 gene polymorphism associated with tardive dyskinesia.Nord J Psychiatry. 2014 Feb;68(2):123-8. doi: 10.3109/08039488.2013.780260. Epub 2013 Jun 24.
• [11] Genetic association analysis of 5-HT(6) receptor gene polymorphism (267C/T) with tardive dyskinesia.Psychiatry Res. 2002 Jun 1;110(2):97-102. doi: 10.1016/s0165-1781(02)00095-1.
• [12] Antipsychotic-induced movement disorders in long-stay psychiatric patients and 45 tag SNPs in 7 candidate genes: a prospective study.PLoS One. 2012;7(12):e50970. doi: 10.1371/journal.pone.0050970. Epub 2012 Dec 4.
• [13] There is no evidence for an association between the serotonin receptor 3A gene C178T polymorphism and tardive dyskinesia in Korean schizophrenia patients.Nord J Psychiatry. 2013 Jun;67(3):214-8. doi: 10.3109/08039488.2012.732114. Epub 2012 Nov 6.
• [14] Analysis of genetic variations in the human melatonin receptor (MTNR1A, MTNR1B) genes and antipsychotics-induced tardive dyskinesia in schizophrenia.World J Biol Psychiatry. 2011 Mar;12(2):143-8. doi: 10.3109/15622975.2010.496870. Epub 2010 Aug 23.
• [15] Antipsychotic-induced tardive dyskinesia: update on epidemiology and management.Curr Opin Psychiatry. 2019 May;32(3):179-184. doi: 10.1097/YCO.0000000000000491.
• [16] The TAAR5 agonist -NETA causes dyskinesia in mice.Neurosci Lett. 2019 Jun 21;704:208-211. doi: 10.1016/j.neulet.2019.04.028. Epub 2019 Apr 12.
• [17] Secondary dystonia and the DYTI gene.Neurology. 1997 Jun;48(6):1571-7. doi: 10.1212/wnl.48.6.1571.
• [18] Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients.Neuropsychobiology. 2004;49(4):167-73. doi: 10.1159/000077360.
• [19] Resting-state Brain Activity Changes Associated with Tardive Dyskinesia in Patients with Schizophrenia: Fractional Amplitude of Low-frequency Fluctuation Decreased in the Occipital Lobe.Neuroscience. 2018 Aug 10;385:237-245. doi: 10.1016/j.neuroscience.2018.06.014. Epub 2018 Jun 20.
• [20] New findings in pharmacogenetics of schizophrenia.Curr Opin Psychiatry. 2018 May;31(3):200-212. doi: 10.1097/YCO.0000000000000417.
• [21] Glial cell line-derived neurotrophic factor receptor alpha 2 (GFRA2) gene is associated with tardive dyskinesia.Psychopharmacology (Berl). 2010 Jun;210(3):347-54. doi: 10.1007/s00213-010-1829-4. Epub 2010 Apr 6.
• [22] Tardive dyskinesia is associated with altered putamen Akt/GSK-3 signaling in nonhuman primates.Mov Disord. 2019 May;34(5):717-726. doi: 10.1002/mds.27630. Epub 2019 Jan 24.
• [23] Deep brain stimulation for tardive syndromes: Systematic review and meta-analysis.J Neurol Sci. 2018 Jun 15;389:55-60. doi: 10.1016/j.jns.2018.02.013. Epub 2018 Feb 5.
• [24] Association study between the neurexin-1 gene and tardive dyskinesia.Hum Psychopharmacol. 2017 Jan;32(1). doi: 10.1002/hup.2568.
• [25] Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness.J Clin Psychopharmacol. 2005 Oct;25(5):448-56. doi: 10.1097/01.jcp.0000177546.34799.af.
• [26] Association study indicates a protective role of phosphatidylinositol-4-phosphate-5-kinase against tardive dyskinesia.Int J Neuropsychopharmacol. 2014 Dec 28;18(6):pyu098. doi: 10.1093/ijnp/pyu098.
• [27] Analysis of genetic variations in the RGS9 gene and antipsychotic-induced tardive dyskinesia in schizophrenia.Am J Med Genet B Neuropsychiatr Genet. 2009 Mar 5;150B(2):239-42. doi: 10.1002/ajmg.b.30796.
• [28] Neuropsychological and psychiatric outcome of GPi-deep brain stimulation in dystonia.Brain Stimul. 2017 Sep-Oct;10(5):994-996. doi: 10.1016/j.brs.2017.06.002. Epub 2017 Jun 9.